Rowan Walrath

Regeneron-backed start-up has $52 million to begin testing its lead candidate in people

The pharma giant will acquire oral peptide developer Nimble Therapeutics

GEMMA Biotherapeutics will put the money toward rare disease drugs

GEMMA Biotherapeutics will put the money toward rare disease drugs

Artificial intelligence start-up PostEra will help the drugmaker design new payloads

Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone payments.

Johnson & Johnson, GSK acquisitions reignite M&A enthusiasm at the J.P. Morgan Healthcare Conference

Johnson & Johnson, GSK acquisitions reignite M&A enthusiasm at the J.P. Morgan Healthcare Conference

The pharma giant is partnering with software firms to imagine new drugs, find targets, and design clinical trials

Executives attending J.P. Morgan conference don’t expect to find easy money in 2025